RecruitingPhase 2NCT07265947

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Sponsor

Tyra Biosciences, Inc

Enrollment

230 participants

Start Date

Dec 22, 2025

Study Type

INTERVENTIONAL

Conditions

Low-grade Upper Tract Urothelial Carcinoma

Summary

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dabogratinib (TYRA-300) 60mg, a drug called Dabogratinib (TYRA-300) 80mg, and others for people with low-grade upper tract urothelial carcinoma. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDabogratinib (TYRA-300) 60mg

Self-administered 60mg dose Oral tablet(s) given daily

DRUGDabogratinib (TYRA-300) 80mg

Self-administered 80mg dose Oral tablet(s) given daily

DRUGDabogratinib (TYRA-300) TBD

To be determined: Self-administered Oral tablet(s) given daily

Locations(17)

Moffitt Cancer Center

Tampa, Florida, United States

The Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Duly Health and Care Chicago

Lisle, Illinois, United States

Urology of Indiana, LLC

Greenwood, Indiana, United States

First Urology

Jeffersonville, Indiana, United States

Greater Boston Urology - Plymouth Care Center

Plymouth, Massachusetts, United States

Urology of St. Louis

St Louis, Missouri, United States

Summit Health - Washington Township

Sewell, New Jersey, United States

Albany Medical College

Albany, New York, United States

Associated Medical Professionals of NY, PLLC

Syracuse, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Central Ohio Urology Group

Gahanna, Ohio, United States

Penn Medicine Radnor

Radnor, Pennsylvania, United States

Urology Associates, P C

Nashville, Tennessee, United States

Urology Austin - Apex Cancer Care - Austin

Austin, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Hospital Universitario Puerta del Mar

Cadiz, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07265947

Related Trials

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

NCT066684939 locations